Cogent Biosciences offers a favorable risk/reward ratio of roughly 6-to-1 and meaningful analyst-implied upside, but the business is cash-burning, quality falls far below the minimum acceptable threshold of 4.0, and nearly all clinical value is concentrated in a single pipeline program — the asymmetry exists without the quality foundation to support a position.
Thesis pillars
- Single Program Binary Risk↓Deteriorating
- Cash Burn Quality Below Floor↓Deteriorating
- Favorable Asymmetry Analyst Upside→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 17, 2026
Cogent Biosciences, Inc. (COGT) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $32.01: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 3.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Below-average business quality; Below long-term trend.
Cogent Biosciences is a clinical-stage biotech developing bezuclastinib, a selective KIT inhibitor, for Systemic Mastocytosis and GIST. The company submitted its first NDA for NonAdvSM in December 2025 and initiated the GIST NDA submission in January 2026; a U.S. commercial... Read more
Sell if holding. Engine safety override at $32.01: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 3.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 61. Score 5.0/10, moderate confidence.
Passes 6/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and earnings proximity 5d<=7d. Suitability: speculative.
About Cogent Biosciences, Inc.
About Cogent Biosciences, Inc.
Cogent Biosciences reported positive top-line results from all three registrational trials for bezuclastinib in 2025: SUMMIT (NonAdvSM), APEX (AdvSM), and PEAK (GIST). The company submitted its first NDA in December 2025 (NonAdvSM), initiated the GIST NDA submission in January 2026, and targets an AdvSM NDA in the first half of 2026. The FDA granted Breakthrough Therapy Designation for bezuclastinib in NonAdvSM in October 2025 and for second-line GIST in January 2026. A U.S. commercial launch is planned for the second half of 2026.
Cogent Biosciences has no product revenue; the company funds operations through equity financing and plans to commercialize bezuclastinib in SM and GIST following regulatory approval. Bezuclastinib is licensed exclusively from Plexxikon Inc., a Daiichi Sankyo subsidiary, under a 2020 license agreement that requires tiered royalties ranging from low- to high-single-digit percentages on annual net sales, aggregate development milestone payments of up to $7.5 million (the first $2.5 million paid in June 2022, $5.0 million triggered in Q4 2025), and regulatory milestones of up to $25.0 million (an additional $15.0 million may become payable within twelve months). The company is building an internal commercial organization to market bezuclastinib in the United States. Early-stage pipeline assets include CGT4859 (FGFR2/3 inhibitor, Phase 1 enrolling), CGT4255 (CNS-penetrant ErbB2 inhibitor, Phase 1 initiated Q4 2025), and CGT6297 (PI3Kα inhibitor, IND submitted Q4 2025). Preclinical KRAS and JAK2 V617F programs have IND submissions planned for 2026.
Show full overview
Cogent's valuation is essentially a single NDA binary: bezuclastinib is the only program at a regulatory stage and the source of all planned near-term revenue. The PEAK trial demonstrated median PFS of 16.5 months versus 9.2 months for sunitinib monotherapy in second-line GIST, reducing the risk of progression or death by 50%. However, there is no guarantee of regulatory approval for any indication, and even an approved bezuclastinib would face competition from Blueprint Medicines' avapritinib (a Sanofi company) and Novartis AG's midostaurin in AdvSM, with market size estimates inherently uncertain for rare-disease indications.
See also: Healthcare · Biotechnology
From Cogent Biosciences, Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-10-28Recent Developments — Cogent Biosciences, Inc.
Latest news
- NEWS Cogent Biosciences Announces Conference Participation and Inducement Equity Grants — fiscal.ai Oct 27, 2026 neutral
- NEWS If You Invested $1000 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today — benzinga Oct 21, 2026
- NEWS Here’s How Much You Would Have Made Owning Cogent Biosciences Stock In The Last 5 Years — benzinga Oct 12, 2026 neutral
- NEWS $1000 Invested In Cogent Biosciences 5 Years Ago Would Be Worth This Much Today — benzinga Oct 2, 2026 neutral
- NEWS Cogent Biosciences Enters Commercial Supply Agreement With Hovione On Sept 1, 2026; To Purchase Minimum Percentages Of B — benzinga Sep 2, 2026 positive
Generated 2026-10-28T11:58:43Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinebezuclastinib program10-K Item 1A: 'Our business is highly dependent on the success of our bezuclastinib program and our ability to discover and develop additional product candidates.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $32.01: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 3.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 61. Prior stop was $29.77. Score 5.0/10, moderate confidence.
Analyst target: $48.56 (+51.7% upside). Prior stop was $29.77. Stop-loss: $29.77.
Concentration risk — Pipeline: bezuclastinib program; Quality below floor (1.5 < 4.0).
Cogent Biosciences, Inc. trades at a P/E of N/A (forward -26.8). TrendMatrix value score: 9.0/10. Verdict: Sell.
18 analysts cover COGT with a consensus score of 4.3/5. Average price target: $56.
What does Cogent Biosciences, Inc. do?Cogent Biosciences is a clinical-stage biotech developing bezuclastinib, a selective KIT inhibitor, for Systemic...
Cogent Biosciences is a clinical-stage biotech developing bezuclastinib, a selective KIT inhibitor, for Systemic Mastocytosis and GIST. The company submitted its first NDA for NonAdvSM in December 2025 and initiated the GIST NDA submission in January 2026; a U.S. commercial launch in the second half of 2026 is planned pending regulatory approval. Bezuclastinib is exclusively in-licensed from Plexxikon Inc. with mid- to high-single-digit royalties on net sales.